# IL-6 inhibition with ziltivekimab in patients at high atherosclerotic risk (RESCUE): a double-blind, randomised, placebo-controlled, phase 2 trial

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/il-6-inhibition-with-ziltivekimab-in-patients-at-high-atherosclerotic-risk/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Paul M. Ridker,Matt Devalaraja,Florian M.M. Baeres,Mads D.M. Engelmann,G. Kees Hovingh,Milana Ivkovic,Larry Lo,Douglas Kling,Pablo E. Pérgola,Dominic S. Raj,Peter Libby,Michael Davidson |
| Citations | 692 |
| DOI | 10.1016/s0140-6736(21)00520-1 |
| Fields | Biochemistry, Genetics and Molecular Biology,Medicine |
| Open Access | true |
| OA Status | green |
| OA URL | https://pure.amsterdamumc.nl/ws/files/212002547/Il-6-inhibition-with-ziltivekimab-in-patients-at-high-atherosclerotic-risk-rescue-a-double-blind-randomised-placebo.pdf |
| OpenAlex ID | https://openalex.org/W3160421219 |
| PMID | 34015342 |
| Type | article |
| Year | 2021 |

## Paper authors

- [Florian M.M. Baeres](https://scholariq.org/researchers/florian-m-m-baeres/)

## Paper journal

- [The Lancet](https://scholariq.org/journals/the-lancet/)

## Paper primary topic

- [Adipokines, Inflammation, and Metabolic Diseases](https://scholariq.org/topics/adipokines-inflammation-and-metabolic-diseases/)

## Paper topics

- [Adipokines, Inflammation, and Metabolic Diseases](https://scholariq.org/topics/adipokines-inflammation-and-metabolic-diseases/)
- [Inflammasome and immune disorders](https://scholariq.org/topics/inflammasome-and-immune-disorders/)
- [Lipoproteins and Cardiovascular Health](https://scholariq.org/topics/lipoproteins-and-cardiovascular-health/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.